Sangamo Biosciences, Inc. (SGMO)
Q2 2012 Earnings Call
July 25, 2012 5:00 pm ET
Elizabeth J. Wolffe, Ph.D. – Senior Director, Corporate Communications
Edward Lanphier – President and Chief Executive Officer
H. Ward Wolff – Executive Vice President and Chief Financial Officer
Philip Gregory – Vice President, Research and Chief Scientific Officer
Geoffrey M. Nichol – Executive Vice President, Research and Development
Liana Moussatos – Wedbush Securities Inc.
Charles Duncan – JMP Securities
Ted Tenthoff – Piper Jaffray
Good afternoon, and welcome to Sangamo BioSciences Teleconference to Discuss Second Quarter 2012 Financial Results. This call is being recorded.
I will now pass you over to the coordinator of this event, Dr. Elizabeth Wolffe, Senior Director of Corporate Communications.
Elizabeth J. Wolffe
Thank you, Kate. Good afternoon, and thank you for joining Sangamo's management team on our conference call to discuss the company's second quarter 2012 financial results. Also present during this call are several members of Sangamo senior management, including Edward Lanphier, President and Chief Executive Officer; Ward Wolff, Executive Vice President and Chief Financial Officer; and Geoff Nichol, Executive Vice President, Research and Development; Philip Gregory, Vice President of Research and Chief Scientific Officer; and Dale Ando, Vice President of Development and Chief Medical Officer.
Following this introduction, Edward will highlight recent activities and the significant events from the past quarter. Ward will then briefly review second quarter financial results, as well as our financial guidance for 2012. Philip and Geoff will provide an update on our ZFP therapeutic program, and finally, Edward will update you on our goals for the rest of 2012. Following that, we will open up the call for questions.